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Abstract: Aims: To explore the associations between cholesterol efflux capacity (CEC), coronary
artery calcium (CAC) score, Framingham risk score (FRS), and antibodies against apolipoproteinA-1
(anti-apoA-1 IgG) in healthy and obese subjects (OS). Methods and Results: ABCA1-, ABCG1-, passive
diffusion (PD)-CEC and anti-apoA-1 IgG were measured in sera from 34 controls and 35 OS who
underwent CAC score determination by chest computed tomography. Anti-apoA-1 IgG ability to
modulate CEC and macrophage cholesterol content (MCC) was tested in vitro. Controls and OS
displayed similar ABCG1-, ABCA1-, PD-CEC, CAC and FRS scores. Logistic regression analyses
indicated that FRS was the only significant predictor of CAC lesion. Overall, anti-apoA-1 IgG were
significantly correlated with ABCA1-CEC (r = 0.48, p < 0.0001), PD-CEC (r = −0.33, p = 0.004), and the
CAC score (r = 0.37, p = 0.03). ABCA1-CEC was correlated with CAC score (r = 0.47, p = 0.004) and FRS
(r = 0.18, p = 0.29), while PD-CEC was inversely associated with the same parameters (CAC: r = −0.46,
p = 0.006; FRS: score r = −0.40, p = 0.01). None of these associations was replicated in healthy controls
or after excluding anti-apoA-1 IgG seropositive subjects. In vitro, anti-apoA-1 IgG inhibited PD-CEC
(p < 0.0001), increased ABCA1-CEC (p < 0.0001), and increased MCC (p < 0.0001). Conclusions:
We report a paradoxical positive association between ABCA1-CEC and the CAC score, with the latter
being inversely associated with PD in OS. Corroborating our clinical observations, anti-apoA-1 IgG
enhanced ABCA1 while repressing PD-CEC, leading to MCC increase in vitro. These results indicate
that anti-apoA-1 IgG have the potential to interfere with CEC and macrophage lipid metabolism, and
may underpin paradoxical associations between ABCA1-CEC and cardiovascular risk.
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1. Introduction
Lately, impaired high-density lipoprotein (HDL) cholesterol efflux capacity (CEC) from
macrophages, involving mainly the adenosine triphosphate (ATP)-binding cassette (ABC) transporter
A1 (ABCA1) pathway, has gained considerable interest as a promising biomarker of atherosclerosis
and cardiovascular (CV)-related risk, both in primary and secondary prevention settings [1–3], and
served as proof of concept that HDL functional measures may provide improved CV risk stratification
over standard lipid profile and other traditional CV risk factors [1–3]. Nevertheless, inverse and
paradoxical positive associations between CEC and incident CV events have been reported in high-risk
populations [4], and patients with metabolic syndrome have been shown to have an increased CEC,
possibly due to increase pre-β-HDL levels [5,6]. To further fuel this controversy, no associations were
retrieved between CEC and coronary artery calcium (CAC) score, either in the general population or in
rheumatoid arthritis patients [3,7]. These contrasting observations relating CEC with CV risk and CAC
score might be influenced by disease state or oxidative stress and immune-mediated inflammation.
Among factors influencing immune-mediated inflammation and related to lipid metabolism,
we and others focused our investigations on antibodies against apolipoprotein A-1 (anti-apoA-1 IgG),
the major protein fraction of HDL regulating ABCA1 activity, as a biomarker of poor general and CV
outcomes, both in primary and secondary prevention settings [8–13]. In parallel, in vitro and animal
studies have shown that anti-apoA-1 IgG could promote inflammation, atherogenesis, myocardial
necrosis, and mice death through interaction with the Toll-like receptor (TLR) 2, 4 and the cluster
of differentiation 14 (CD14) complex [14–18]. Accordingly, we demonstrated in obese but otherwise
healthy subjects that anti-apoA-1 IgG were independent predictors of coronary artery lesion upon chest
computed tomography [19]. Several groups have shown that these autoantibodies could also promote
atherogenesis by affecting HDL anti-oxidant properties [20–24], and recently anti-apoA-1 IgG against
the c-terminal part of the protein was found to be inversely associated with fibroblasts CEC [25].
In this pilot study, we explored whether specific pathways of HDL CEC (ABCG1-mediated,
ABCA1-mediated, passive diffusion) could be differentially associated with the CAC score in healthy
obese and non-obese participants, and whether anti-apoA-1 IgG are associated with a specific HDL
CEC pathway modification on macrophages.
2. Experimental Section
2.1. Study Population and Design
The current investigation follows as sub-analysis of a previous published study [19], including
48 non-obese subjects (BMI < 30 kg/m2) and 43 obese subjects (BMI ≥ 30 kg/m2), without known
traditional CV risk factors (such as arterial hypertension, smoking, and diabetes mellitus, anamnestic
notion of variant angina, family history of premature coronary artery disease), clinically patent
cardiovascular/systemic disease, or CV treatment (statins, any cardiac or vasoactive medication). From
these 91 Subjects, 14 samples were missing from non-obese participants and 8 samples were missing
from obese subjects, leaving 69 subjects available for HDL CEC determination. As reported earlier,
“before inclusion in the cardiac perfusion assessment test, study participants underwent a complete
visit, including a physical examination, electrocardiogram, blood pressure measurements, and blood
puncture in a fasting state. Following inclusion, each study participant underwent multidetector
computed tomography (MDCT) and CAC assessment. The study was approved by the University
Hospitals of Geneva Institutional Review Board (protocol number 07-183), and each participant
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signed the approved informed consent form. This study has been conducted in compliance with the
Declaration of Helsinki [19].
2.2. Study Endpoints
Two predetermined endpoints were considered for this pilot study. The primary endpoint
was to test the ability of CEC to predict the presence of any coronary artery calcification on chest
computed tomography (CT) scan, as described below. The secondary endpoint was to explore the
possible association between anti-apoA-1 IgG and CEC. All CT scan data were assessed by two senior
cardiologists blinded to the participants’ biochemical data.
2.3. Assessment of Coronary Artery Calcification by Chest CTscan
In the first step of the perfusion assessment, a 64-slice multidetector computed tomography (MDCT)
(64-sliceBiograph HiRez TruePoint Positron Emission Tomography/Computed Tomography (PET-CT)
scanner, Siemens, Erlangen, Germany) was performed to determine the CAC score. The scanner was
operated in the single slice mode with an image acquisition time of 100 ms and a Section thickness
of 3 mm. Prospective electrocardiogram (ECG) triggering was done at 55% of the R-R interval.
Contiguous slices to the apex of the heart were obtained. CAC was considered present if three or
more contiguous pixels with a signal intensity of >130 Hounsfield Unit were identified. The size of
the lesion was automatically calculated, and the CAC was scored using the Agatston algorithm. The
CAC was computed across all lesions denoted within the left main, left anterior descending (LAD), left
coronary circumflex (LCx), and right coronary artery (RCA), and the sum of all lesion scores yielded
the total CAC score [26]. As recommended, we used the CAC scoring system in a binary fashion (CAC
present or absent) [26,27]. Accordingly, any Agatston score above 0 was considered as a present CAC
lesion [26,27].
2.4. Biochemical Analyses
A conventional lipid profile and high-sensitive C-Reactive Protein (hsCRP) profile were performed
on routine autoanalyzers. Low-density lipoprotein (LDL) cholesterol levels were derived from the
conventional Friedwald equation. Anti-apoA-1 IgG serum levels were measured as previously
described [8,9,11–13]. Briefly, Maxi-Sorb plates (Nunc) were coated with purified, human-derived
delipidated apoA-1 (20 µg/mL; 50 µL/well) for 1 h at 37 ◦C. After 3 washes with phosphate buffered
saline (PBS)/2% bovine serum albumin (BSA; 100µL/well), all wells were blocked for 1 h with 2% BSA at
37 ◦C. Samples were diluted 1 to 50 in PBS/2% BSA and incubated for 60 min. Additional patient samples
at the same dilution were also added to an uncoated well to assess individual nonspecific binding.
After 6 further washes, 50 µL/well of signal antibody (alkaline phosphatase-conjugated anti-human
IgG; Sigma-Aldrich, Saint Louis, MO, USA) diluted 1:1000 in PBS/2% BSA solution were incubated for
1 h at 37 ◦C. After 6 more washes (150 µL/well) with PBS/2% BSA solution, the phosphatase substrate
p-nitrophenyl phosphate disodium (50 µL/well; Sigma-Aldrich) dissolved in diethanolamine buffer
(pH 9.8) was added. Each sample was tested in duplicate, and absorbance, determined as the optical
density at 405 nm (OD405 nm), was measured after 20 min of incubation at 37 ◦C (FilterMax, Molecular
Devices, San Jose, CA, USA). The corresponding nonspecific binding value was subtracted from the
mean absorbance value for each sample. Anti-apoA-1 IgG seropositivity cutoff was predefined as
previously validated and set at an optical density (OD) value of 0.6 and 37% of the positive control
value, as described earlier [8,9,11–13]. OD values ranged from 0 to 1.3, and corresponding index values
were between 0 and 84.9%.
Pre-β-HDL levels were measured using a quantitative enzyme-linked immunosorbent assay
(ELISA) kit for pre-β-HDL detection in human plasma [28], following the manufacturer’s instruction
(Sekisui Diagnostic, Darmstadt, Germany). The coefficient of variation was 3.1% to 5.3% for individual
analytical runs, and 4.9% to 9.1% between different analytical runs.
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2.5. Serum HDL Cholesterol Efflux Capacity (CEC)
All serum samples were stored at−80 ◦C. The aliquots were slowly defrosted in ice. Four cholesterol
efflux pathways were evaluated in cell cultures: total CEC (in J774 mouse macrophages treated with
0.3 mm cAMP for 18 h to up-regulate ABCA1 expression) [1]; passive diffusion (PD)-CEC (in J774 mouse
macrophages, basal conditions) [29]; ABCA1-CEC (as a difference between total efflux and PD) [30];
ABCG1-CEC (in hABCG1-expressing Chinese hamster ovary cells, CHO-K1, as efflux difference
between hABCG1-expressing and parent CHO-K1 control cells) [31]. In all determinations, cells
were labeled with [1,2-3H]-cholesterol in the presence of acyl CoA: cholesterol acyl tranferase (ACAT)
inhibitor (2 µg/mL, Sandoz 58035) for 24 h. The efflux was promoted for 4 h (6 h for ABCG1-CEC) to
2% (v/v) serum samples. Serum HDL CEC was expressed as a percentage of the radioactivity released
to the medium in 4 h (6 h for ABCG1-CEC) over the total radioactivity incorporated by cells. Control
samples were run to confirm the responsiveness of cells. Background efflux, evaluated in the absence
of acceptors, was subtracted from each samples value. Serum samples were determined in triplicate,
while a standard pool of human serum from our laboratory (SN1) permitted correction for inter-assay
variability and a second serum standard pool (SN2) was used to determine inter-assay variability [29].
2.6. Antibody Anti-apoA-1 Modulation of Cellular Cholesterol Efflux
The efflux process was evaluated in J774 cells as previously described. Following the ABCA1
upregulation with cyclic adenosine monophosphate (cAMP) we incubated cells, during the efflux time
(4 h), with 25 µg/mL of anti-apoA-1 IgG. The efflux was promoted to either 10 µg/mL of apo-A-1 or 2%
(v/v) of human serum standard [32].
2.7. Measurement of Intracellular Cholesterol Content
J774 cells were cultured in 10% fetal calf serum (FCS) in RPMI cell medium at 37 ◦C in 5% CO2.
To perform the experiments, cells were seeded in 24-well plates at a density of 2 × 105 cells/well for 24 h.
Cells were exposed for 24 h to either 10% (v/v) whole serum and control IgG or anti-apoA-1 IgG 40µg/mL.
Cellular cholesterol content before and after serum exposure was measured as previously described [33].
Briefly, at the end of the experiment, cell monolayers were washed with Phosphat-Buffered Salin
(PBS) and lysed in 0.5 mL of a 1% sodium cholate solution in water supplemented with 10 U/mL
DNase. Cholesterol was than measured fluorimetrically using the Amplex Red Cholesterol Assay Kit
(Molecular Probes, Eugene, OR, USA) as described by the manufacturer. The amount of cholesterol in
each well was measured by comparison with a cholesterol standard curve included in each experiment.
An aliquot of the cell lysates was also taken to measure cell protein by a modified Lowry method [34].
Cell cholesterol content after exposure of cells to serum and immunoglobulin G (IgG) was expressed as
µg of cholesterol /mg protein.
2.8. Antibody Anti-apoA-1 Modulation of Membrane Free Cholesterol: Assay of Cholesterol Oxidase
Cholesterol oxidase treatment was essentially as previously described [35]. Briefly, cells were
labelled with 3 µCi/mL [3H] cholesterol. Cholesterol oxidase (1 U/mL) was added, and cells were
incubated for 4 h. Lipid was extracted with isopropanol, and radioactive cholesterol and cholestenone
were separated using thin-layer chromatography and quantified.
2.9. Anti-apoA-1 IgG Modulation of Cellular Cholesterol Esterification: ACAT Activity
Cells were treated as previously described for the measurement of intracellular cholesterol content.
Cholesterol esterification was evaluated as the incorporation of radioactivity into cellular cholesteryl
esters after addition of [14C]-oleate-albumin complex [36]. At the end of incubation, cells were washed
with PBS and lipids were extracted with hexane/isopropanol (3:2). The extracted lipids were separated
by thin layer chromatography (TLC) (isoctane/diethyl ether/acetic acid, 75:25:2, v/v/v). Cholesterol
radioactivity in the spots was determined by counting liquid scintillation.
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2.10. Measurement of Free Cholesterol Content in Cell Supernatant
Free cholesterol in supernatant was measured using the fluorometric method Amplex® Red
Cholesterol Assay Kit (Molecular Probe, Eugene, OR, USA) following the manufacturer’s instruction.
The experiments were conducted without an ACAT inhibitor.
2.11. Statistical Analyses
Analyses were performed using Statistica software (StatSoft, Tulsa, OK, USA). Normally,
distributed clinical data are presented as mean ± standard deviation (SD), whereas data following a
non-normal distribution are presented as median and interquartile range (IQR). Accordingly, means
were compared using bilateral student T test, and medians were compared with the Mann-Whitney-test.
Proportions were compared using two-tailed exact Fischer test. Correlations between variables were
assessed using Spearman test. Due to the limited sample size, adjusted analyses were limited to the
different forms of cholesterol efflux analyzed and the 10-year Framingham risk score (FRS) for coronary
heart disease risk prediction [37] (allowing the aggregation of all traditional CV risk factors within a
single continuous variable). Cholesterol efflux and intracellular cholesterol data were expressed as
mean ± SD. Treatment groups were compared using an unpaired two tailed Student’s t-test. Because of
the explorative nature of this work with predefined endpoints, Bonferroni correction was not applied.
Logistic regression analyses were used to assess associations between the presence of any CAC lesion
and CEC, or anti-apoA-1 IgG as variables. In this model, the presence of any CAC lesion was set as the
dependent variable. Associations are presented as odds ratios (OR) and corresponding 95% confidence
intervals (95% CI). A p value below 0.05 was considered as statistically significant.
3. Results
3.1. Study Characteristics
Baseline demographic characteristics are presented in Table 1. As shown in this table, obese
participants had lower levels of HDL, but higher triglycerides, hsCRP, and pre-βHDL levels when
compared to non-obese subjects. No significant differences were found between control and obese
subjects in terms of CEC mediated by ABCG1, ABCA1, or PD pathways and total (ABCA1 + PD) CEC,
and no difference was observed between these two groups for the CAC score, the number of coronary
artery lesions, or the presence of any lesion identified in chest CT scans. On the other hand, obese
participants tended to have higher anti-apoA-1 IgG levels and a significantly higher anti-apoA-1 IgG
positivity rate. Interestingly, anti-apoA-1 IgG positive participants (n = 6) were only observed in the
obese subjects. No other significant association with any of the other parameters tested was retrieved
(Table 1).






(n = 34) * p Value
Age, mean (+/−SD) 44 (11.4) 44.6 (12.0) 43.5 (11.0) 0.61
Male Gender; n (%) 42 (60.8) 23 (65.7) 19 (55.8) 0.46
Weight in Kg, mean (+/−SD) 97.5 (26.37) 116 (19.3) 74.4 (12.5) <0.001
Height in cm, mean (+/−SD) 74 (9.3) 173 (9.4) 172.2 (9.5) 0.56









FRS > 10%; n (%) 7 (10.1) 6 (17) 1 (2.9) 0.10
Chest CT:
Total CAC score, mean (+/−SD) 4.9 (15.8) 4.65 (14.8) 5 (17) 0.75
Number of CAC lesions, mean (+/−SD) 0.28 (0.75) 0.28 (0.71) 0.26 (0.79) 0.74
Presence of any CAC lesion; n (%) 10 (14.4) 6 (17.1) 4 (11.7) 0.73







(n = 34) * p Value
Lipid profile:
Total cholesterol in mg/dL, mean (+/−SD) 198.9 (36.4) 198.5 (41.4) 202.1 (31.5) 0.69
LDL cholesterol in mg/dL mean (+/−SD) 127.9 (32.2) 126.9 (36.9) 133.9 (26.7) 0.42
HDL cholesterol in mg/dL, mean (+/−SD) 47.1 (13.0) 42.1 (11.5) 50.4 (13.9) 0.04
Triglycerides in mg/dl, mean (+/−SD) 97.5 (73.2) 122.8 (70.8) 83.0 (67.0) <0.001
Pre-β-HDL in µg/mL 42.6 (16.62) 49.2 (17.26) 35.6 (12.8) <0.001
Cholesterol Efflux Capacity:
ABCG1-mediated, mean (+/−SD) 4.04 (1.2) 4.04 (0.89) 3.85 (1.49) 0.96
ABCA1-mediated, mean (+/−SD) 3.98 (1.49) 4.18 (1.34) 3.67 (1.61) 0.18
Total, mean (+/-SD) 13.73 (1.55) 13.5 (1.57) 13.80 (1.57) 0.64























Note: * p values were obtained by comparing obese versus non-obese subjects. For normally distributed parameters,
p values were computed according to student t-test and for non-parametric parameters U-Mann Whitney test was
used. Proportions were compared using two-tailed exact Fischer test. Abbreviations: SD = standard deviation; IQR
= interquartile range; BMI = Body mass index; FRS = Framingham Risk Score; CT = Computed tomography; CAC =
Coronary artery calcium; LDL = Low-density lipoprotein; HDL = High-density lipoprotein; ABCG1 = ATP-binding
cassette subfamily G member 1; ABCA1 = ATP-binding cassette transporter 1; OD = Optical density; hsCRP =
High-sensitivity C-reactive Protein.
3.2. Associations between CEC Pathways, CAC Score, Framingham Risk Score, Pre-Beta-HDL,
and hsCRP Levels
ABCG1 CEC was not found to be associated with CAC score or FRS, nor with pre-β-HDL levels
in any of the study groups (Table 2). ABCA1 CEC was found to be positively associated with CAC
score and the number of CAC lesions in overall subjects (r = 0.26, p = 0.02), and the strength of this
association seemed to increase in obese subjects (r = 0.47, p = 0.004), whereas it was lost in non-obese
participants (Table 2). The only significant association retrieved between CEC and pre-β-HDL levels
was between pre-β-HDL and PD-CEC (r = 0.39, p = 0.02), which was only observed in obese subjects.
Furthermore, FRS correlated positively with ABCA1-CEC in overall and control subjects, but not in
obese participants, whereas we observed an inverse correlation between PD-CEC, CAC score, and FRS
in overall and obese participants, but not in non-obese subjects (Table 2). HsCRP levels did not correlate
with any forms of CEC in any subgroups (Table 2), nor with the FRS (r = 0.09; p = 0.43), with CAC score
(r = −0.04; p = 0.75), or with the number of CAC lesions (r = −0.03; p = 0.77). This absence of correlation
between hsCRP, FRS, the CAC score, and the CAC lesion was unchanged in obese and non-obese
individuals (data not shown). Because of the significant correlation shown between CAC score and
anti-apoA-1 IgG [19], as well as between CAC score/lesions and ABCA1- and PD-CEC, we performed
a sensitivity analysis after excluding anti-apoA-1 IgG positive patients (n = 6) in the obese subgroup in
order to see if excluding high anti-apoA-1 IgG values could change the associations between different
forms of CEC with FRS, number of CAC lesions, and CAC score, as well as with pre-β-HDL. Due to
the non-significant aforementioned associations with hsCRP levels and any forms of CEC, hsCRP
was not considered in our sensitivity analyses. As shown in Table 2, after excluding anti-apoA-1
IgG seropositive subjects, the correlations between CAC score/lesion and ABCA1-CEC and PD-CEC
remained significant and of the same order of magnitude, whereas the significant association between
FRS and ABCA1 was lost. The correlation between FRS and PD-CEC was unchanged. This does
not point to anti-apoA-1 IgG as a key determinant of the associations retrieved between CAC score,
ABCA1-CEC, and PD-CEC. Finally, if logistic regression analyses indicated that ABCA1-CEC, PD-CEC,
and FRS were all significant predictors of CAC lesion in univariate analysis, the FRS was found to be
the only independent predictor of CAC lesion in the overall cohort (Table 3). Given the limited study
sample size, these analyses were not performed in the obese and non-obese subgroups separately.
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CAC score 0.02 0.84 −0.03 0.82 0.10 0.57
Nr of CAC lesions 0.02 0.86 −0.04 0.81 0.09 0.61
Framingham RS −0.01 0.90 0.06 0.70 −0.09 0.59
Pre-β-HDL −0.22 0.09 −0.19 0.27 −0.23 0.18
hsCRP 0.007 0.94 0.04 0.77 0.22 0.20
ABCA1-mediated CEC vs.:
CAC score 0.26 0.02 0.47 0.004 0.05 0.76
Nr of CAC lesions 0.26 0.02 0.47 0.004 0.04 0.80
Framingham RS 0.30 0.01 0.18 0.29 0.40 0.01
Pre-β-HDL −0.08 0.48 −0.15 0.38 −0.25 0.15
hsCRP 0.05 0.44 0.04 0.79 −0.12 0.47
Passive Diffusion vs.:
CAC score −0.30 0.01 −0.46 0.006 −0.10 0.53
Nr of CAC lesions −0.29 0.01 −0.45 0.006 −0.09 0.60
Framingham RS −0.33 0.006 −0.40 0.01 −0.22 0.21
Pre-β-HDL 0.15 0.20 0.39 0.02 0.06 0.72
hsCRP −0.01 0.90 0.06 0.63 0.17 0.35
Correlations after excluding anti-apoA-1 IgG seropositive individuals in obese participants (n = 29)
Correlations R Value (Spearman) p Value
ABCG1-mediated CEC vs.:
CAC score 0.01 0.72
Nr of CAC lesions 0.01 0.97
Framingham RS 0.06 0.72
Pre-β HDL −0.13 0.49
ABCA1-mediated CEC vs.:
CAC score 0.39 0.03
Nr of CAC lesions 0.39 0.03
Framingham RS 0.24 0.20
Pre-β HDL −0.14 0.48
Passive diffusion vs.:
CAC score −0.39 0.04
Nr of CAC lesions −0.39 0.04
Framingham RS −0.45 0.009
Pre-β-HDL 0.41 0.03
Table 3. Logistic regression analyses for CAC lesion prediction
Univariate Analyses Multivariate Analyses
Continuous Predictors Odds Ratio 95% CI p Odds Ratio 95% CI p
ABCG1 CEC 1.10 0.64–1.91 0.72 1.02 * 0.51–2.05 0.94
ABCA1 CEC 1.17 1.17–3.13 0.009 1.38 ** 0.67–2.86 0.38
Passive diffusion 0.56 0.32–0.97 0.03 0.78 *** 0.37–1.54 0.44
Framingham RS 1.31 1.13 0.004 1.27 **** 1.09–1.49 0.002
Note: * Adjusted for ABCA1 CEC, Passive diffusion and FRS; ** adjusted for ABCG1-CEC, passive diffusion, and FRS;
*** adjusted for ABCG1-CEC and ABCA1-CEC, and FRS; **** adjusted for ABCA1, ABCG1, and passive diffusion.
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3.3. Associations between Anti-apoA-1 IgGs, Specific CEC Pathways, Pre-β-HDL, and hsCRP Levels
Spearman correlations showed a positive association between ABCA1-CEC and anti-apoA-1
IgG (r = 0.48, p < 0.001) and a negative association between PD-CEC and these antibodies (r = −0.33;
p = 0.004; Table 4) on our overall participants samples. The anti-apoA-1 IgG association with
ABCA1-CEC remained significant for the obese and non-obese subgroups. Nevertheless, if the
association with PD-CEC was unchanged in non-obese subjects, it was lost in obese participants
(Table 4). No associations were retrieved between pre-β-HDL serum levels and anti-apoA-1 IgG,
nor between these antibodies and hsCRP (data not shown).








Correlations R value p value R value p value R value p value
Anti-apoA-1 IgG (OD) vs.:
CAC score 0.21 0.09 0.37 0.03 0.01 0.91
Nr of CAC lesions 0.21 0.09 0.37 0.03 0.02 0.88
Framingham Risk Score −0.03 0.81 −0.03 0.82 −0.11 0.51
ABCG1-mediated CEC −0.16 0.17 −0.23 0.18 −0.10 0.54
ABCA1-mediated CEC 0.48 0.00002 0.49 0.002 0.44 0.007
Passive diffusion −0.33 0.004 −0.29 0.09 −0.36 0.03
Pre-β-HDL 0.17 0.89 −0.04 0.81 −0.06 0.9
3.4. Anti-apoA-1 IgG-Mediated Modulation of Cellular Cholesterol Efflux
To further evaluate the possible impact of anti-apoA-1 IgG on CEC, we measured ABCA1-CEC
and PD-CEC using standard serum or apoA-1 in J774 macrophages without cAMP stimulation in
presence of anti-apoA-1 antibodies during the efflux time. As shown in Figure 1, cells incubated with
the antibody showed an increased ABCA1-mediated efflux to the acceptors (4.28 ± 0.29 vs. 6.45 ± 0.45
p < 0.0001 to apoA1 as acceptor; 1.16 ± 0.15 vs. 1.81 ± 0.19 p < 0.0001 to human serum as acceptor).
Conversely, the presence of the anti-apoA-1 IgG reduced the passive cellular efflux diffusion to both
apoA-1 and human serum (0.77 ± 0.10 vs. 0.48 ± 0.11 p < 0.0001; 6.49 ± 0.05 vs. 4.67 ± 0.66 p < 0.0001).
3.5. Modulation of Anti-apoA-1 IgGs on Intracellular and Membrane Cholesterol Content
To understand the net effect of such dual modification of anti-apoA-1 IgGs on cellular cholesterol
balance, we measured the impact of anti-apoA-1 IgGs on intracellular cholesterol content according to
a previously validated method. As shown in Figure 2, anti-apoA-1 IgGs induced a significant increase
in intracellular cholesterol content compared to control IgGs and baseline conditions.
To better investigate the possible anti-apoA-1 IgG-mediated passive diffusion inhibition, we look
at the free cholesterol content in the membrane of J774 cells after four hour anti-apoA-1 IgG stimulation.
As shown in Figure 3, anti-apoA-1 IgGs significantly reduced the free cholesterol membrane content
when compared to the control IgGs or to the untreated condition. In the same experimental conditions,
we observed a significant reduction of the free cholesterol content in the supernatant counterpart in the
presence of anti-apoA-1 IgGs (Figure 4). Since ACAT is the key enzyme for the cholesterol esterification
and its cellular redistribution, we measured the ACAT activity in the presence of anti-apoA-1 IgGs or
control antibodies. As shown in Figure 5, anti-apoA-1 IgGs (and not the control IgGs) significantly
increased ACAT activity.
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Figure 1. Cholesterol efflux from J774 to various acceptors in presence of anti-apoA-1 (AAA1) IgG. (a,b)
The cells were activated with cAMP to measure the specific efflux from ABCA1 to serum or apoA-1
as acceptors after 4 h incubation. Data are expressed as the mean ± SD of the measure ents done in
triplicate and repeated four times (n = 4). Statistical differences were determined by one-way analysis
of variance (one-way ANOVA), with p ≤ 0.05 being considered significant. (c,d) The cells were not
activated in order to quantify the passive cellular efflux diffusion to both apoA-1 or human serum. The
percentage of cholesterol efflux is shown. Data are expressed as the mean ± SD of the measurements
done in triplicate and repeated four times (n = 4). Statistical differences were determined by one-way
analysis of variance (one-way ANOVA), with p ≤ 0.05 being considered significant.
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ANOVA), with p ≤ 0.05 being considered significant.
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Figure 3. Free cholesterol in membrane. Monolayers were labeled with 3 µCi/mL [3H] cholesterol
for 24 h in RPMI medium with 10% FCS, control IgGs or anti-apoA-1 IgGs 40 µg/mL. Cells were then
washed and incubated with 1 U/mL cholesterol oxidase enzyme in Dulbecco’s Phosphate Buffered
Saline (DPBS) for 4 h at 37 ◦C. Data are expressed as the mean ± SD of the measurements done in
triplicate and repeated three times (n = 3). Statistical differences were determined by one-way analysis
of variance (one-way ANOVA), with p ≤ 0.05 being considered significant.
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Taken together, these results indicate that the presence of anti-apoA-1 IgG on J774 macrophages
enhances ACAT activity leading to increased intracellular esterified cholesterol pools, and decreases
membrane free-cholesterol content. Such decrease in membrane free-cholesterol content reduce the
cholesterol gradient, leading to a decrease in passive diffusion PD followed by the reduction of
free-cholesterol content in cell supernatants. In this context, the increase in ABCA1-efflux in the
presence of anti-apoA-1 IgG can be interpreted as the consequence of increased intracellular lipid pools.
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4. Discussion
In this study, we extend previous findings by demonstrating that on top of being significantly
associated with higher CAC [19], anti-apoA-1 IgG levels are inversely associated with PD-CEC and
positively with ABCA1-CEC in healthy obese subjects, despite the absence of ABCA1-CEC, ABCG1-CEC,
and PD-CEC differences between obese and control participants. This apparently counterintuitive
clinical observation derived from this small case-control study prompted us to evaluate the possible
direct impact of anti-apoA-1 IgG on normal serum and apoA-1 CEC on macrophages, and on
macrophage cholesterol content.
Corroborating our clinical observations, these in vitro investigations indicated that, per se, these
autoantibodies could at the same time inhibit PD-CEC and potentiate ABCA1-CEC. PD efflux consists of
the simple diffusion of free/unesterified cholesterol molecules across the membrane through the aqueous
phase following their concentration gradient between the membrane and HDL/apoA-1, and accounts
for the majority of total macrophage efflux (up to 80%) in normocholesterolemic conditions [38,39].
On the other hand, ABCA1-mediated efflux is an active pathway facilitating the transfer of unesterified
cholesterol specifically to lipid-poor apoA-1, and represents up to 60% of total macrophage cholesterol
efflux when activated by increased intracellular cholesterol load [38–40]. For this reason, determining
the net effect of simultaneously blocking and activating these two important HDL CEC pathways at
the cellular level was the key to providing a sound interpretation of our clinical and functional in vitro
observations. As anti-apoA-1 IgG leads to increased intracellular cholesterol content in macrophages
after 24 h of stimulation, we currently postulate that the anti-apoA-1 IgG overdriving mechanism
consists of ACAT stimulation, leading to intracellular esterified cholesterol accumulation, decreasing
the amount of membrane free-cholesterol available, and thus diminishing the cholesterol gradient
requested for PD-CEC. In this context, the increase in ABCA1 efflux can be ascribed to a feedback loop
aiming at preventing cellular cholesterol accumulation. Nevertheless, other possibilities cannot be
formally excluded, and the exact mechanisms by which anti-apoA-1 IgG stimulates ACAT activity
are still elusive. Several non-exclusive hypotheses are discussed below. Firstly, one can postulate an
upstream mechanism, where anti-apoA-1 IgG could, per se, stimulate ACAT activity. With ACAT being
an endoplasmic reticulum intracellular protein, an indirect effect may be evoked. Indeed, as ACAT
deficiency has been shown to increase TLR4 expression and function in hepatocytes stellate cells [41],
we cannot exclude the fact that anti-apoA-1 IgG-mediated TLR2/TLR4 stimulation may interfere
with ACAT activity, although this hypothesis is currently devoid from of experimental evidence.
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Alternatively, as ACAT activation is known to occur in response to cholesterol overload [42], any factor
increasing either the intracellular cholesterol synthesis or uptake could be susceptible to increase
ACAT activity. Therefore, knowing whether anti-apoA-1 IgG could affect HGMCoA reductase or
LDL-receptor expression and function is currently under investigation.
Alternatively, we can consider the anti-apoA-1 IgG-mediated ACAT stimulation as a downstream
consequence of mechanisms related to PD-CEC inhibition. Given the complexity of PD-CEC, where
desorption of free cholesterol molecules from the cell plasma membrane into the surrounding aqueous
phase is the rate-limiting step [38–40], there are several possibilities, including those in direct relation
with apoA-1 [40]. Firstly, by stabilizing lecithin-cholesterol acyltransferase (LCAT) activity, apoA-1
maintains a favourable cholesterol gradient. One could hypothesize that anti-apoA-1 IgG may
decrease LCAT stability, attenuating the cholesterol gradient and followed by PD-CEC attenuation.
Secondly, as apoA-1 can also facilitate the maintenance of such gradient, either by acting as an
acceptor for cholesterol molecules diffusing away from the cell surface, or by mediating the process
of membrane microsolubilization, we can also envisage an antibody-mediated interference of one of
these acceptor-related processes [38]. Indeed, as c-terminal (c-ter) part of apoA-1 is known to mediate
membrane microsolubilization important for PD-CEC to occur [43], and because anti-apoA-1 IgG in
humans is biased against the c-ter part of apoA-1 [44], we cannot rule-out a direct and antagonistic
effect of anti-apoA-1 IgG on PD-CEC. Finally, as mentioned above, the increased ABCA1-CEC in
the presence of anti-apoA-1 IgG is likely to represent a homeostatic feedback loop. Nevertheless,
as ABCA1 activity is regulated by apoA-1′s interaction with an epitope on the c-terminal part of
apoA-1 [45], we cannot formally rule out a direct agonistic effect of these antibodies on ABCA1, or an
indirect effect mediated through the antibody-induced macrophage interleukin-6 (IL-6) production
known to increase ABCA1 efflux [46]. Despite these current mechanistic knowledge gaps requiring
further detailed investigations, these results indicate that anti-apoA-1 IgG-induced ACAT stimulation
followed by PD-CEC inhibition represent another mechanism by which these auto-antibodies can
promote atherogenesis.
The second notable finding of the present study is the observation that in obese participants,
macrophage ABCA1-CEC is positively associated with coronary atherosclerosis burden quantified by
the CAC score, whereas no such association was retrieved in healthy controls. Although somehow
contrasting with data published in primary and secondary prevention settings [1–3], these results are in
line with previous observations in metabolic syndrome and rheumatoid arthritis [4–6], and lend weight
to the notion that depending on disease-related systemic factors, the associations between macrophage
ABCA1-CEC and coronary atherosclerosis burden are not necessarily straightforward. As metabolic
syndrome patients share many pathophysiological similarities with obese patients, the existence of
such a paradoxical association was suspected, but still remained to be demonstrated. Furthermore,
providing PD-CEC results in parallel with ABCA1-CEC was found to be instrumental in facilitating
the interpretation of these results. Indeed, the inverse association between CAC score and macrophage
PD-CEC suggest that the lower the PD efflux, the higher the level of intracellular cholesterol, and
thus atherosclerosis burden. In this context, the anti-apoA-1 IgG-dependent ABCA1-CEC increase, in
fact, may not sufficiently compensate for the PD inhibition ascribed to anti-apoA-1 IgG. Furthermore,
as our in vitro data demonstrated a substantial influence of anti-apoA-1 IgG on PD-CEC through
ACAT stimulation, we performed a sensitivity analysis excluding anti-apoA-1 IgG seropositive subjects
in the obese subgroup, which yielded similar results overall. Taken together, these results indicate
that considering ABCA1-CEC without considering other concomitant functional effluxes may lead to
erroneous conclusions. These results also suggest that the presence of anti-apoA-1 IgG may represent
a new systemic factor susceptible to altering the usual association between ABCA1-CEC and CV risk.
This study has several limitations. The first one relates to the low number of subjects enrolled in
this study, raising possible power issues when it comes to the plausibility of non-significant findings.
Nevertheless, despite this power limitation, the significant findings derived from this cohort enabled
us to generate hypotheses that were tested and validated in vitro, providing valuable insights to
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correctly interpret counterintuitive associations. A second limitation of this study is that we were not
able to decipher the exact molecular mechanisms by which anti-apoA-1 IgG could stimulate ACAT
activity and inhibit PD-CEC, and we did not explore their possible ability to modulate key cholesterol
homeostasis regulating genes, which is currently under investigation (Pagano S. et al., under review).
A further limitation is the fact that due to limited human sample availability, we could not evaluate
the effects of human purified apoA-1 IgG in this study. Nevertheless, as we previously demonstrated
that the commercial anti-human apoA-1 IgGs used in this study were promoting the same effects as
human-purified IgG fraction containing high levels of these autoantibodies in vitro [13,18], and because
these autoantibodies have been consistently used in different validated and published animal and
in vitro studies [11–19], we expect similar impacts on in vitro lipid metabolism to occur by using human
purified anti-apoA-1 IgG, even if not formally demonstrated. Finally, being focused on atherogenesis
and foam cell formation, we did not evaluate whether the anti-apoA-1 IgG effects on lipid metabolism
could be reproduced by other cell types, such as hepatocytes, and did not measure the scavenger
B-I-related CEC.
5. Conclusions
In conclusions, the results of this study indicate that in healthy obese subjects there is a paradoxical
positive association between CAC score and ABCA1-CEC, and a negative association between PD-CEC
and CAC score. These associations could be partly explained by the propensity of anti-apoA-1 IgG to
inhibit PD-mediated cholesterol efflux through ACAT stimulation and promote foam cell formation,
notwithstanding an enhancing effect on ABCA1-mediated cholesterol efflux. Although preliminary,
these results highlight the importance of simultaneously considering the different CEC pathways and
using a translational approach for proper ABCA1-CEC interpretation.
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